Osteopontin mediates an MZF1-TGF-β1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer

Oncogene

Volumn 34, Issue 37, 2015, Pages 4821-4833

  Weber, C E ^a,b   Kothari, A N ^a,b   Wai, P Y ^a,b   Li, N Y ^a,b   Driver, J ^a,b   Zapf, M A C ^a,b   Franzen, C A ^a,b   Gupta, G N ^a,b   Osipo, C ^b   Zlobin, A ^b   Syn, W K ^a,c,d   Zhang, J ^b   Kuo, P C ^a,b   Mi, Z ^a,b  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^c BARTS HEALTH NHS TRUST   (United Kingdom)

^d Institute of Hepatology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; MESSENGER RNA; MYELOID ZINC FINGER 1; OSTEOPONTIN; PROTEIN; RNA POLYMERASE II; TENASCIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; KRUPPEL LIKE FACTOR; MZF1 PROTEIN, HUMAN;

ARTICLE; BIOLUMINESCENCE; BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CELL ADHESION; CELL MIGRATION; CELL TRANSFORMATION; CHROMATIN IMMUNOPRECIPITATION; COCULTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MCF 7 CELL LINE; MESENCHYMAL STEM CELL; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR BLOCKING; REGULATORY MECHANISM; TATA BOX; TUMOR MICROENVIRONMENT; XENOGRAFT; ANIMAL; BREAST TUMOR; CANCER STEM CELL; DRUG EFFECTS; FEMALE; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHYSIOLOGY; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

ANIMALS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; FIBROBLASTS; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MCF-7 CELLS; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; OSTEOPONTIN; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1; TUMOR CELLS, CULTURED;

EID: 84941316326     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.410     Document Type: Article

References (82)

1. Mishra PJ, Humeniuk R, Medina DJ, Alexe G, Mesirov JP, Ganesan S et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res 2008; 68: 4331-4339.
2. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS ONE 2009; 4: e4992.
3. Bierie B, Moses HL. Tumour microenvironment: TGF[beta]: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006; 6: 506-520.
4. Worthington JJ, Klementowicz JE, Travis MA. TGFbeta: a sleeping giant awoken by integrins. Trends Biochem Sci 2011; 36: 47-54.
5. Liu Z, Bandyopadhyay A, Nichols RW, Wang L, Hinck AP, Wang S et al. Blockade of autocrine TGF-beta signaling inhibits stem cell phenotype, survival, and metastasis of murine breast cancer cells. J Stem Cell Res Ther 2012; 2: 1-8.
6. Dumont N, Liu B, Defilippis RA, Chang H, Rabban JT, Karnezis AN et al. Breast fibroblasts modulate early dissemination, tumorigenesis, and metastasis through alteration of extracellular matrix characteristics. Neoplasia 2013; 15: 249-262.
7. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003; 9: 416-423.
8. Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 2008; 27: 103-118.
9. Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A et al. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 2006; 12: 3337-3343.
10. Mi Z, Guo H, Wai PY, Gao C, Wei J, Kuo PC. Differential osteopontin expression in phenotypically distinct subclones of murine breast cancer cells mediates metastatic behavior. J Biol Chem 2004; 279: 46659-46667.
11. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997; 3: 605-611.
12. Cook AC, Tuck AB, McCarthy S, Turner JG, Irby RB, Bloom GC et al. Osteopontin induces multiple changes in gene expression that reflect the six 'hallmarks of cancer' in a model of breast cancer progression. Mol Carcinog 2005; 43: 225-236.
13. Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M, Lindmark-Mansson H. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 1087-1097.
14. McAllister SS, Gifford AM, Greiner AL, Kelleher SP, Saelzler MP, Ince TA et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008; 133: 994-1005.
15. Elkabets M, Gifford AM, Scheel C, Nilsson B, Reinhardt F, Bray MA et al. Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest 2011; 121: 784-799.
16. Anderberg C, Li H, Fredriksson L, Andrae J, Betsholtz C, Li X et al. Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. Cancer Res 2009; 69: 369-378.
17. Mi Z, Bhattacharya SD, Kim VM, Guo H, Talbot LJ, Kuo PC. Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis 2011; 32: 477-487.
18. Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J 1993; 7: 1475-1482.
19. Kojima Y, Acar A, Eaton EN, Mellody KT, Scheel C, Ben-Porath I et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci USA 2010; 107: 20009-20014.
20. Kim SJ, Glick A, Sporn MB, Roberts AB. Characterization of the promoter region of the human transforming growth factor-beta 1 gene. J Biol Chem 1989; 264: 402-408.
21. Qi W, Gao S, Wang Z. Transcriptional regulation of the TGF-?1 promoter by androgen receptor. Biochem J 2008; 416: 453-462.
22. Morris JF, Hromas R, Rauscher FJ 3rd. Characterization of the DNA-binding properties of the myeloid zinc finger protein MZF1: two independent DNAbinding domains recognize two DNA consensus sequences with a common G-rich core. Mol Cell Biol 1994; 14: 1786-1795.
23. Hromas R, Morris J, Cornetta K, Berebitsky D, Davidson A, Sha M et al. Aberrant expression of the myeloid zinc finger gene, MZF-1, is oncogenic. Cancer Res 1995; 55: 3610-3614.
24. Tsai S-J, Hwang J-M, Hsieh S-C, Ying T-H, Hsieh Y-H. Overexpression of myeloid zinc finger 1 suppresses matrix metalloproteinase-2 expression and reduces invasiveness of SiHa human cervical cancer cells. Biochem Biophys Res Commun 2012; 425: 462-467.
25. Rafn B, Nielsen Christian F, Andersen Sofie H, Szyniarowski P, Corcelle-Termeau E, Valo E et al. ErbB2-driven breast cancer cell invasion depends on a complex signaling network activating myeloid zinc finger-1-dependent cathepsin B expression. Mol Cell 2012; 45: 764-776.
26. Hsieh Y-H, Wu T-T, Tsai J-H, Huang C-Y, Hsieh Y-S, Liu J-Y. PKC? expression regulated by Elk-1 and MZF-1 in human HCC cells. Biochem Biophys Res Commun 2006; 339: 217-225.
27. Gaboli M, Kotsi PA, Gurrieri C, Cattoretti G, Ronchetti S, Cordon-Cardo C et al. Mzf1 controls cell proliferation and tumorigenesis. Genes Dev 2001; 15: 1625-1630.
28. Mi Z, Guo H, Russell MB, Liu Y, Sullenger BA, Kuo PC. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther 2009; 17: 153-161.
29. Mi Z, Guo H, Kuo PC. Identification of osteopontin-dependent signaling pathways in a mouse model of human breast cancer. BMC Res Notes 2009; 2: 119.
30. Bhattacharya SD, Mi Z, Kim VM, Guo H, Talbot LJ, Kuo PC. Osteopontin regulates epithelial mesenchymal transition-associated growth of hepatocellular cancer in a mouse xenograft model. Ann Surg 2012; 255: 319-325.
31. Korpal M, Yan J, Lu X, Xu S, Lerit DA, Kang Y. Imaging transforming growth factor-[beta] signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med 2009; 15: 960-966.
32. Pang H, Lu H, Song H, Meng Q, Zhao Y, Liu N et al. Prognostic values of osteopontin-c, E-cadherin and beta-catenin in breast cancer. Cancer Epidemiol 2013; 37: 985-992.
33. Patani N, Jouhra F, Jiang W, Mokbel K. Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. Anticancer Res 2008; 28: 4105-4110.
34. Xu LN, Xu BN, Cai J, Yang JB, Lin N. Tumor-associated fibroblast-conditioned medium promotes tumor cell proliferation and angiogenesis. Genet Mol Res 2013; 12: 5863-5871.
35. Mao Y, Keller E, Garfield D, Shen K, Wang J. Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev 2012; 32: 303-315.
36. Huang WH, Chang MC, Tsai KS, Hung MC, Chen HL, Hung SC. Mesenchymal stem cells promote growth and angiogenesis of tumors in mice. Oncogene 2012; 32: 4343-4354.
37. Brauer HA, Makowski L, Hoadley KA, Casbas-Hernandez P, Lang LJ, Roman-Perez E et al. Impact of tumor microenvironment and epithelial phenotypes on metabolism in breast cancer. Clin Cancer Res 2012; 19: 571-585.
38. Boxall SA, Jones E. Markers for characterization of bone marrow multipotential stromal cells. Stem Cells Int 2012; 2012: 975871.
39. Quante M, Tu SP, Tomita H, Gonda T, Wang SSW, Takashi S et al. Bone marrowderived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011; 19: 257-272.
40. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006; 5: 1597-1601.
41. Erez N, Truitt M, Olson P, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-[kappa]B-dependent manner. Cancer Cell 2010; 17: 135-147.
42. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449: 557-563.
43. Otto WR, Wright NA. Mesenchymal stem cells: from experiment to clinic. Fibrogenesis Tissue Repair 2011; 4: 20.
44. Mishra PJ, Banerjee D. Activation and differentiation of mesenchymal stem cells. Methods Mol Biol 2011; 717: 245-253.
45. Kidd S, Spaeth E, Watson K, Burks J, Lu H, Klopp A et al. Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS ONE 2012; 7: e30563.
46. Davis C, Price R, Acharya G, Baudino T, Borg T, Berger FG et al. Hematopoietic derived cell infiltration of the intestinal tumor microenvironment in ApcMin/+ mice. Microsc Microanal 2011; 17: 528-539.
47. Direkze NC, Hodivala-Dilke K, Jeffery R, Hunt T, Poulsom R, Oukrif D et al. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res 2004; 64: 8492-8495.
48. Helluin O, Chan C, Vilaire G, Mousa S, DeGrado WF, Bennett JS. The activation state of alphavbeta 3 regulates platelet and lymphocyte adhesion to intact and thrombin-cleaved osteopontin. J Biol Chem 2000; 275: 18337-18343.
49. O'Regan A, Berman JS. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol 2000; 81: 373-390.
50. Tuck AB, O'Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 1998; 79: 502-508.
51. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001; 7: 4060-4066.
52. Tuck AB, Chambers AF. The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia 2001; 6: 419-429.
53. Yu K-N, Minai-Tehrani A, Chang S-H, Hwang S-K, Hong S-H, Kim J-E et al. Aerosol delivery of small hairpin osteopontin blocks pulmonary metastasis of breast cancer in mice. PLoS ONE 2010; 5: e15623.
54. Tuck AB, Chambers AF, Allan AL. Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem 2007; 102: 859-868.
55. Shevde LA, Samant RS, Paik JC, Metge BJ, Chambers AF, Casey G et al. Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis 2006; 23: 123-133.
56. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S et al. ETA-1: an early component of type-1 immunity. Science 2000; 287: 860-864.
57. Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. Mol Pathol 1999; 52: 189-196.
58. Wai PY, Kuo PC. The role of Osteopontin in tumor metastasis. J Surg Res 2004; 121: 228-241.
59. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994; 145: 610-623.
60. Matsuzaki H, Shima K, Muramatsu T, Ro Y, Hashimoto S, Shibahara T et al. Osteopontin as biomarker in early invasion by squamous cell carcinoma in tongue. J Oral Pathol Med 2007; 36: 30-34.
61. Gao M-Q, Kim BG, Kang S, Choi YP, Park H, Kang KS et al. Stromal fibroblasts from the interface zone of human breast carcinomas induce an epithelialmesenchymal transition-like state in breast cancer cells in vitro. J Cell Sci 2010; 123: 3507-3514.
62. Udagawa T, Puder M, Wood M, Schaefer BC, D'Amato RJ. Analysis of tumorassociated stromal cells using SCID GFP transgenic mice: contribution of local and bone marrow-derived host cells. FASEB J 2006; 20: 95-102.
63. Wang H, Cao F, De A, Cao Y, Contag C, Gambhir SS et al. Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging. Stem Cells 2009; 27: 1548-1558.
64. Casey T, Eneman J, Crocker A, White J, Tessitore J, Stanley M et al. Cancer associated fibroblasts stimulated by transforming growth factor beta1 (TGF-?1) increase invasion rate of tumor cells: a population study. Breast Cancer Res Treat 2008; 110: 39-49.
65. Quante M, Tu SP, Tomita H, Gonda T, Wang SS, Takashi S et al. Bone marrowderived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011; 19: 257-272.
66. Hawinkels LJ, Paauwe M, Verspaget HW, Wiercinska E, van der Zon JM, van der Ploeg K et al. Interaction with colon cancer cells hyperactivates TGF-beta signaling in cancer-associated fibroblasts. Oncogene 2012; 33: 97-107.
67. Su G, Sung KE, Beebe DJ, Friedl A. Functional screen of paracrine signals in breast carcinoma fibroblasts. PLoS ONE 2012; 7: e46685.
68. Nicholas SB, Liu J, Kim J, Ren Y, Collins AR, Nguyen L et al. Critical role for osteopontin in diabetic nephropathy. Kidney Int 2010; 77: 588-600.
69. Vetrone SA, Montecino-Rodriguez E, Kudryashova E, Kramerova I, Hoffman EP, Liu SD et al. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J Clin Invest 2009; 119: 1583-1594.
70. Wolak T, Kim H, Ren Y, Kim J, Vaziri ND, Nicholas SB. Osteopontin modulates angiotensin II-induced inflammation, oxidative stress, and fibrosis of the kidney. Kidney Int 2009; 76: 32-43.
71. Szalay G, Sauter M, Haberland M, Zuegel U, Steinmeyer A, Kandolf R et al. Osteopontin: a fibrosis-related marker molecule in cardiac remodeling of enterovirus myocarditis in the susceptible host. Circ Res 2009; 104: 851-859.
72. Kohan M, Breuer R, Berkman N. Osteopontin induces airway remodeling and lung fibroblast activation in a murine model of asthma. Am J Respir Cell Mol Biol 2009; 41: 290-296.
73. Miyazaki K, Okada Y, Yamanaka O, Kitano A, Ikeda K, Kon S et al. Corneal wound healing in an osteopontin-deficient mouse. Invest Ophthalmol Vis Sci 2008; 49: 1367-1375.
74. Syn WK, Choi SS, Liaskou E, Karaca GF, Agboola KM, Oo YH et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 2011; 53: 106-115.
75. Lenga Y, Koh A, Perera AS, McCulloch CA, Sodek J, Zohar R. Osteopontin expression is required for myofibroblast differentiation. Circ Res 2008; 102: 319-327.
76. Mudduluru G, Vajkoczy P, Allgayer H. Myeloid zinc finger 1 induces migration, invasion, and in vivo metastasis through Axl gene expression in solid cancer. Mol Cancer Res 2010; 8: 159-169.
77. Hsieh YH, Wu TT, Huang CY, Hsieh YS, Liu JY. Suppression of tumorigenicity of human hepatocellular carcinoma cells by antisense oligonucleotide MZF-1. Chin J Physiol 2007; 50: 9-15.
78. Que-Gewirth NS, Sullenger BA. Gene therapy progress and prospects: RNA aptamers. Gene Ther 2007; 14: 283-291.
79. Ireson CR, Kelland LR. Discovery and development of anticancer aptamers. Mol Cancer Ther 2006; 5: 2957-2962.
80. Wong TY, Liew G, Mitchell P. Clinical update: new treatments for age-related macular degeneration. Lancet 2007; 370: 204-206.
81. Mak GW, Lai WL, Zhou Y, Li M, Ng IO, Ching YP. CDK5RAP3 is a novel repressor of p14ARF in hepatocellular carcinoma cells. PLoS ONE 2012; 7: e42210.
82. Keng PC, Allalunis-Turner J, Siemann DW. Evaluation of cell subpopulations isolated from human tumor xenografts by centrifugal elutriation. Int J Radiat Oncol Biol Phys 1990; 18: 1061-1067.